CMD-601

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameCMD-601
Drug Alias NameT-cell receptor-modified therapy (UCL/Cell Medica)anti-survivin TCR T-cell therapy (UCL/Cell Medica)autologous T-cell therapy (Cell Medica)CMD-601
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionHuman leukocyte antigen modulatorsBaculoviral IAP repeat-containing protein 5 modulators
TargetsBaculoviral IAP repeat-containing protein 5Human leukocyte antigen
Therapy Area/IndicationsOvarian NeoplasmsPancreatic NeoplasmsStomach Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity College London
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKuur Therapeutics LimitedUniversity College London
Active IndicationsN/A
Inactive IndicationsOvarian NeoplasmsPancreatic NeoplasmsStomach Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A